Erschienen in:
30.03.2017 | Case Report
Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis
verfasst von:
Georgios Makragiannis, Kaveh Vahdani, Ester Carreño, Richard W. J. Lee, Andrew D. Dick, Adam H. Ross
Erschienen in:
International Ophthalmology
|
Ausgabe 2/2018
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To report a case of juxtafoveal choroidal neovascularization in a patient with candida chorioretinitis successfully treated with intravitreal bevacizumab.
Results
A 45-year-old woman previously treated for candida chorioretinitis was presented with reduced vision in the left eye. The patient was investigated with ophthalmoscopy, fluorescein angiography, and optical coherence tomography (OCT). Following initial treatment, fundus examination, fluorescein angiography, and OCT of the right eye revealed a secondary juxtafoveal classic choroidal neovascularization. Following a single intravitreal injection of bevacizumab, the patient had excellent visual recovery, with absence of subretinal or intraretinal fluid in the OCT.
Conclusions
Bevacizumab was effective in treatment of choroidal neovascularization associated with candida chorioretinitis.